Protocol: MC10- PTL-103, Revision 00 1 
Confidential  
A 
Study to Evaluate the Performance, Usability, and Reliability of a Novel Device 
for Continuous Collection of Physiological Data in Healthcare and Remote 
Settings  
Pr
otocol Number:  MC10 -PTL- 103 
Revision 00 
Date :  June 21, [ADDRESS_608179]:  BioStamp nPoint  
Re
gulatory Status: Limited to investigational use only  
Spons
or: MC10, Inc.  
[ADDRESS_608180], Bldg. 3  
Lexington, MA [ZIP_CODE]  
This study will be conducted in compliance with the ethical principles of the Declaration of 
Helsinki ( 64th WMA General Assembly, Fortaleza, Brazil October 2013), ISO [ZIP_CODE]:2011,  
and ICH -GCP Guidelines.  
CONFIDENTIALITY STATEMENT  
This study is confidential in nature. All information related to this study is considered 
proprietary and should not be made available to anyone  not directly involved in this 
study. Authorized recipi[INVESTIGATOR_474593]-
investigators, other health care personnel necessary to conduct the study, and the 
presiding Institutional Review Boards  and governing regulatory agencies. The personnel 
provided with data from this study are hereby [CONTACT_214686]. Release of these data to individuals other than those listed above requires the 
prior written permission of  MC10, Inc.  [STUDY_ID_REMOVED]
   
 
 
 
Protocol: MC10- PTL-103, Revision 00  4 
Confidential  
PROTOCOL SYNOPSIS  
Title A Study to Evaluate the Performance, Usability, and Reliability of a Novel System 
for Continuous Collection of Physiological Data  in Healthcare and Remote 
Settings   
Investigational Device  BioStamp nPoint ™ 
Indications for Use  The BioStamp nPoint  system is a wireless remote monitoring system intended for 
use by [CONTACT_474618]. These physiological data 
include heart rate, heart rate variability , respi[INVESTIGATOR_1487], activity (including step 
count and activity classification), and posture (body position relative to gravity). 
The system is also intended for measurement of surface electromyography and 
to monitor limb or body movements during daily liv ing and sleep. Data are 
transmitted wirelessly from the Sensors for storage and analysis.  
The device is intended for use on general care patients who are 18 years of age 
or older as a general patient monitor to provide physiological information. The 
data f rom the BioStamp nPoint  system are intended for use by [CONTACT_474619], at the discretion of a 
qualified healthcare professional, as an aid to diagnosis and treatment. The 
device is not intended for use on critical care patients.  
Study Type  Interventional  
Study Phase  Pi[INVESTIGATOR_474594] 510(k) submission  
Study Objective  The primary objective of the clinical investigation is to:  
• Evaluate the accuracy of BioStamp nPoint  system algorithm 
measurements and to evaluate the adhesion (reliability) of BioStamp 
nPoint Sensors . 
 
Study Design  A single -site, non- significant risk, open- label, prospective non- randomized clinical 
investigation designed to validate the accuracy of the various physiological 
parameters that the Wearable Sensor Patches  acquire and the system processes 
as well as to validate the performance of the skin adhesive  
Enrollment Size  Twenty -five (25) subjects minimally will be enrolled in the study.  
Number of Sites  One site in the [LOCATION_002].  
Subject  Population  Healthy adult subjects will be recruited to participate in this study.   
Effectiveness  
Endpoints   The effectiveness endpoints for this study are the various types of measurements 
made by [CONTACT_474620].  All effectiveness endpoints to be 
statistically summarized will be collected using the BioStamp nPoint  and are as 
follows:  
 
• Heart Rate (bpm)  
• Heart Rate Variability (RMSSD1 (msec) and LF/HF Ratio2) 
                                                 
 
1 RMSSD: root -mean- square of successive difference of the time intervals between successive heartbeats.  
   
 
 
 
Protocol: MC10- PTL-103, Revision 00  5 
Confidential  
• Respi[INVESTIGATOR_1516] (average respi[INVESTIGATOR_1487])  
• Activity Classification (activities – sleep, standing, sitting, lying, walking 
and other)  
• Activity Parameters - total step counts in a [ADDRESS_608181]  
• Sleep (sleep onset time (hours, minutes, and seconds), sleep wake time 
(hours, minutes, and seconds))  
• Posture Classification (sleep posture, stationary posture standing, 
stationary posture sitting)  
 
For each endpoint, the BioStamp nPoint measurements will be compared to a 
similar FDA approved measurement device, other simplistic measurement 
devices, or to independent observer me asurements.  The FDA approved 
measurement devices for this study are the Actiheart heart rate reference device 
and the Capnostream ™ portable respi[INVESTIGATOR_172655].  
 
Endpoint Variable Group  Measurement Comparator  
Heart Rate  Actiheart Device  
Heart Rate Variability  Actiheart Device  
Respi[INVESTIGATOR_474595]10 sensor and system data to be uploaded to the MC10 cloud by [CONTACT_474621] .  MC10 system and reference device to be returned to the clinic al site 
by [CONTACT_474622].   
All clinical study source documents to be retained at the site.  Copi[INVESTIGATOR_014], where 
applicable, to be provided to MC10.  Reference device data to be downloaded on 
site and both retained on site and provided to MC10. Any external electronic 
storage (e.g. DVD) to be retained by [CONTACT_474623] s.  
Safety All adverse events (AEs) reported during the evaluation period will be collected 
and summarized.  Serious AEs (SAEs) will be reported in accordance with US 
Code of Federal Regulation requirements . 
Inclusion Criteria  
 Subject s must meet all of the following criteria to be eligible for participation in the 
study:  
Inclusion Criteria  
1. Male or female volunteers, at least 18 years  of age at the time of 
screening visit;  
2. Fluent in English;  
3. The subject is willing to comply with the protocol specified evaluat ions; 
4. Subject is willing and cognitively able to sign informed consent  
Exclusion Criteria  Subject s must be excluded from participation in this study if any of the following 
criteria are met:  
Exclusion Criteria  
1. Pregnancy ; 
                                                                                                                                                              
 
2 LF/HF ratio: the ratio of power in the low -frequency (LF, 0.04- 0.15 Hz) and high- frequency (HF, 0.15- 0.4 Hz) bands of heart rate 
variability in the frequency domain.  
   
 
 
 
Protocol: MC10- PTL-103, Revision 00  6 
Confidential  
2. Positive urine drug screen  
3. History  of active (clinically significant) skin disorders;  
4. History of allergic response to silicones or adhesives;  
5. Subjects with electronic implants of any kind (e.g. pacemaker)  
6. History of sleep disorders or self -reported insomni a or other sleep 
conditions ; 
7. Broke n, damaged or irritated skin or rashes near the sensor application 
sites;  
8. Subjects that are MC10 employees or shareholders, or a spouse or child 
of an MC10 employee or shareholder;  
9. Subjects who are physically or cognitively unable to normally perform 
activities of daily living , assessed  at the discretion of the investigator.  
Remuneration  Subject s will receive $50  for on- site screening that results in screen fail or 
enrollment, and a subsequent $ 1050 for successfully completing the study, where 
completion is defined as completing the baseline clinic visit, wearing the sensors 
for two days, returning the sensors to the coordinators , and completing the 
usability survey .   
Study Duration / 
Follow -up Period  A supervised session which includes one awake and two  night -time sleep periods  
with observation periods throughout ; thus a total evaluation duration of 
approximately [ADDRESS_608182] -
sensor removal.  
Data Analysis Plan   
The follow ing analysis populations will be defined for the study:  
 
• Intent -to-Measure (ITM) Population –  The ITM population will consist of 
all subjects who are enrolled in the study and for which the ability of each 
measurement device to measure the subject has been  established.  
 
• Safety Population – The safety population will consist of all subjects who 
are enrolled in the study . 
 
The ITM population will be the primary analysis set for all effectiveness analyses.  
The safety population will be used for the analysis of all safety variables and 
baseline characteristics.  
 
For each effectiveness endpoint, the BioStamp nPoint measurements will be 
compared to the noted comparator device or to independent observer 
measurements.  
 
For pairs of measurements collected on the co ntinuous scale (quantitative to 
quantitative comparisons), scatter plots with the 45 degree line of agreement 
superimposed will be constructed from paired observations from the two sources 
(BioStamp nPoint vs comparator) along with Bland- Altman plots of the data.  The 
mean absolute error (MAE) and the root -mean- square error (RMSE) estimates of 
agreement will be calculated for each comparison.  The standard deviations of 
each of the agreement measures will also be computed.   
 
For pairs of measurements colle cted on a categorical scale (qualitative to 
qualitative comparisons), two- way tables of agreement will be constructed for 
each comparison.  The agreement percentage will be computed for each table.  
 
The number and percentage of sensor patches in each categ ory of the adhesion 
   
 
 
 
Protocol: MC10- PTL-103, Revision [ADDRESS_608183] Floor  
Lexington, MA [ZIP_CODE]  
 
  

   
 
 
 
Protocol: MC10- PTL-103, Revision [ADDRESS_608184] OF ABBREVIATIONS  .................................................................................................................... 12 
1.0 BACKGROUND AND RATIONALE  ................................................................................................ 13 
2.0 DEVICE DESCRIPTION ................................................................................................................ 13 
2.1 Principles of Operation  ........................................................................................................ 14 
2.2 Indications for Use .............................................................................................................. 14 
3.0 STUDY PURPOSE AND OBJECTIVES ......................................................................................... 15 
4.0 STUDY ENDPOINTS  ..................................................................................................................... 15 
4.1 Effectiveness Endpoints  ...................................................................................................... 15 
4.2 Safety  .................................................................................................................................. 17 
5.0 STUDY DEVICES  ........................................................................................................................... 17 
6.0 STUDY DESIGN  ............................................................................................................................. 19 
6.1 Study Du ration  .................................................................................................................... 19 
6.2 Schedule of Events  ............................................................................................................. 20 
7.0 STUDY POPULATION  ................................................................................................................... 22 
7.1 Number of Subjects ............................................................................................................. 22 
8.0 STUDY PROCEDURES & ASSESSMENTS ................................................................................. [ADDRESS_608185] Eligibility, Pre- Screening and Exclusions  ............................................................... 23 
8.5 Written Informed Consent  ................................................................................................... 23 
8.6 Screening and Baseline (Day 0) Evaluation  ....................................................................... [ADDRESS_608186] Enrollment  .............................................................................................................. 23 
8.8 Study Assessments – In Clinic –  Visit 1 (Supervised)  ........................................................ 24 
8.9 Study Assessments – Remote (Unobserved)  ..................................................................... 27 
   
 
 
 
Protocol: MC10- PTL-103, Revision 00  9 
Confidential  
8.10  Study Assessments – In Clinic –  Visit 2 (Supervis ed) ........................................................ [ADDRESS_608187] Early Discontinuation / Withdrawal of Subjects  ..................................................... 29 
10.0  Risk / Benefit Analysis  .................................................................................................................... [ADDRESS_608188] e Size  ........................................................................................................................ 30 
11.3  Effectiveness Variables  ....................................................................................................... 30 
11.4  Analysis Populations  ........................................................................................................... 32 
11.5  Analysis Subgroups  ............................................................................................................ 32 
11.6  Statistical and Analytical Plans  ........................................................................................... 32 
11.7  Handling Missing Data  ........................................................................................................ 33 
11.8  Interim Analysis  ................................................................................................................... 33 
12.0  DATA MANAGEMENT  ................................................................................................................... 33 
12.1  Data Flow  ............................................................................................................................ 33 
12.2  Data Collection  .................................................................................................................... 34 
12.3  Data Processing  .................................................................................................................. 34 
13.0  MONITORING AND QUALITY CONTROL PROCEDURES  .......................................................... 34 
13.1  Monitoring and Auditing  ...................................................................................................... 34 
13.2  Device Labeling  ................................................................................................................... 35 
13.3  Device Accountability  .......................................................................................................... 35 
14.0  ADVERSE EVENTS  ....................................................................................................................... 35 
   
 
 
 
Protocol: MC10- PTL-103, Revision 00  10 
Confidential  
14.1  Definitions  ........................................................................................................................... 35 
14.2  Adverse Event Reporting  .................................................................................................... 36 
14.3  Adverse Event Reporting  .................................................................................................... 37 
14.4  Device Deficiency  ................................................................................................................ 38 
14.5  Anticipated Device Related Effects  ..................................................................................... 38 
15.0  MEDICAL MONITORING  ............................................................................................................... 38 
16.0  STUDY ADMINISTRATION  ........................................................................................................... 38 
16.1  Statement of Compliance  .................................................................................................... 38 
16.2  IRB Approval  ....................................................................................................................... 39 
16.3  Informed Consent  ................................................................................................................ 39 
16.4  Amending the Protocol  ........................................................................................................ 39 
16.5  Protocol Deviations/Violations and Medical Emergencies  .................................................. [ADDRESS_608189] Retention  ................................................................................................................ 40 
16.8  Criteria for Terminating Study  ............................................................................................. 41 
16.9  Criteria for Suspending/Terminating an Investigational Site  ............................................... 41 
16.10  Sponsor Responsibilities  ..................................................................................................... 41 
16.11  Investigator Responsibilities  ............................................................................................... 41 
17.0  REVISION HISTORY ..................................................................................................................... 43 
18.0  BIBLIOGRAPHY  ............................................................................................................................. 44 
 
  
   
 
 
 
Protocol: MC10- PTL-103, Revision [ADDRESS_608190] of Figures  
Figure 1:  Illustration of BioStamp nPoint Sensor  ........................................................................................ 14 
Figure 2:  Anatomical Locations for Investigational and Reference Devices  ............................................... 18 
Figure 3:  Study Design Flow Chart  ............................................................................................................. [ADDRESS_608191] of Tables  
Table 1: Endpoint Variable Group and Measurement Comparator  ............................................................. 15 
Table 2: Posture Variable and Classification  .............................................................................................. 16 
Table 3: Sensor Adhesion Rating Scale  ..................................................................................................... 16 
Table 4:  Devices for Study Activities  ........................................................................................................... 18 
Table 5: Schedule of Events  ....................................................................................................................... 21 
Table 6: Application Activities  ...................................................................................................................... 24 
Table 7: Activity Classification Activities  ..................................................................................................... 25 
Table 8: Heart Rate Activities  ...................................................................................................................... 26 
Table 9: Irritation Rating Scale  .................................................................................................................... 27 
Table 10: Endpoint Variable Group and Measurement Comparator  ........................................................... 31 
Table 11: Posture Variable vs Classification  ............................................................................................... 32 
Table 12: Adverse Event Definitions  ........................................................................................................... 35 
 
  
   
 
 
 
Protocol: MC10- PTL-103, Revision [ADDRESS_608192] Patient – First Visit  
GCP  Good Clinical Practice  
HF/LF  Ratio of power in the high -frequency and low -frequency  
HR Heart Rate  
HRV  Heart Rate Variability  
ICH International Conference on Harmonization  
ICS Intercostal Space  
IFU Instructions for Use  
IRB Institutional Review Board  
ISO International Organization for Standardization  
MAE  Mean Absolute Error  
MDDS  Medical Device Data System  
NSR  Non-Significant Risk  
RMSSD  Root -Mean -Square Standard D eviation  
SADE  Serious Adverse Device Effect  
SAE Serious Adverse Event  
SAP Statistical Analysis Plan  
SS Safety Set  
[LOCATION_003]DE  Unanticipated Serious Adverse Device Effect  
WSP  Wearable Sensor Patch  
 
 
 
  
 
  
 
 
 
 
 
Protocol: MC10- PTL-103, Revision [ADDRESS_608193] as well as his/her  current 
condition.   Some assessments are subjective, or rely on a patient’s memory and perception.  Other 
assessments are limited to a specific time interval in a particular environment, like a clinic, preventing 
accurate longitudinal assessment of fluctuations in physiologic al parameters.  This is particularly true of 
measurements taken by [CONTACT_474624], which may limit not only the setting for the 
measurement but may also affect the subject and change the outcome of the measurement itself.  
Wearable sensors have the potential to enable longitudinal, objective monitoring of clinical signs  across 
patient populations, but conventional wearable devices are typi[INVESTIGATOR_474596], packaged 
electronics, which may compromise overall subject  comfort , are often plainly visible when worn in public, 
and can interfere with activities of daily living and sleep.  Finally, emergence of smartphone and wrist -
based sensing has led to potential improvements in access and ease of use, but t hemselves carr y 
limitations in night -time sensing or in creating lower -extremity insight.  Consequently, there is a need for 
assessment tools that are unobtrusive and provide clinical quality, medical grade continuous 
assessments  from multiple body locations.    
Conformal,  body -worn sensors may provide an easy -to-use and objective alternative.  Previously, studies 
have shown that wearable sensors can be used to provide greater insight into neurological (e.g. 
Parkinson’s disease1, Huntington’s disease2, multiple sclerosis3), sleep4 (e.g. periodic limb movements, 
respi[INVESTIGATOR_1516]), cardiac monitoring5 and orthopedics (e.g . physical rehabilitation6) movement and biopotential 
measurements. These studies have demonstrated that data can be collected in an unobtrusive way in 
remote settings, supporting the possibility of providing more robust, data- based evidence to the clinician 
and thus to the patient.  
The BioStamp nPoint  system combines a t raditional, electronic platform for collecting Patient Reported 
Outcomes with multiple , location- agnostic  sensors in an adhesive bandage- like form factor . These 
sensors are flexible enough to conform to the human body and eliminate the profound mismatch in 
physical properties at the interface between conventional wearable devices and the human body.  This  
new class of soft, conformal electronics and sensors interface better with the surface of  the body to 
minimize discomfort and optimize skin coupling over prolonged use and multiple data- gathering locations . 
The potential for  both in- clinic and remote,  longitudinal, multi- sensor, multi -modal, passive and prescribed 
biometric data tracking is noteworthy.    
This first clinical evaluation aims to evaluate the accuracy, reliability, and ease of use of the BioStamp 
nPoint  system  as well as the safety , fidelity  and tolerability of the BioStamp nPoint  Sensors.  
2.0 DEVICE DESCRIPTION 
The BioStamp nPoint  system is a wireless remote monitoring platform intended for use by [CONTACT_474625]. The system is designed principally for dat a collectio n during research studies al though may be 
used wherever and whenever collection of the relevant data is needed.  
 
   
 
 
 
Protocol: MC10- PTL-103, Revision 00  14 
Confidential  
 
Figure 1: Illustration  of BioStamp nPoint Sensor  
The BioStamp nPoint  system centers on body -worn Wearable Sensor Patches ( “Sensors”, “ WSPs ”) which 
can be worn in both in clinic  (“supervised”)  and remote (“unsupervised”)  settings for up to 24 hours  at a 
time, and can be worn repeatedly for multiple days . Study facilitators (either researchers or physicians) 
set up data collection studies using a web- based study configuration tool, called the Web Portal.  For in -
clinic uses, the BioStamp nPoint  system includes a n Investigator  Tablet Application that study facilitators 
use to connect to and configure Sensor s. When used at home, study subjects interact with the system 
through a Mobile Phone Application, the Link App .  The Link Hub is used to charge and synchronize data 
from the Sensors .  The BioStamp nPoint  system includes an algorithm package that delivers processed 
metrics on general activity classification, heart rate, heart rate variability, posture, sleep, and respi[INVESTIGATOR_474597].  
2.1 Principles of Operation  
When the facilitator configures the study design via the Web Portal, the study configuration is 
transferred to the Investigator Tablet App (and Link App for remote studies).  The Investigator Tablet 
App and Link App are automatically configured for the specific study d esign, and when connected to 
Sensor s, configure them per the study design. When user entered data including activity annotations 
and survey answers are sent from the Investigator Tablet App or Link  App, the data travel to an 
MDDS storage system and are  then accessible to facilitators via th e Web Portal, which pulls the data 
from the MDDS storage system.  Sensor  data is transferred to the MDDS s torage through the Link 
Hub and Link App. If the algorithm package was activated in the study, the algorithm module retrieves 
the data from the MDDS, processes the data and generates metrics that are returned to the MDDS 
system for storage. Study facilitators can access all study data (raw and processed) through the Web 
Portal.  
2.2 Indication s for Use  
The BioStamp nPoint  system is a wireless remote monitoring system intended for use by [CONTACT_474626]. These physiological data include heart rate, heart rate variability , respi[INVESTIGATOR_1487], activity 
(including step count and activity classification), and posture (body position relative to gravity). The 
system is also intended for measurement of surface electromyography and to monitor limb or body 
movements during daily liv ing and sleep. Data is transmitted wirelessly from the Sensors for storage 
and analysis.  
 
The device is intended for use on general care patients who are 18 years of age or older as a general 
patient monitor to provide physiological information. The data f rom the BioStamp nPoint  system are 
intended for use by [CONTACT_474627], at the 
discretion of a qualified healthcare professional, as an aid to diagnosis and treatment. The device is 
not intended for use on critical care patients.  
 
  

   
 
 
 
Protocol: MC10- PTL-103, Revision 00  15 
Confidential  
3.0 STUDY PURPOSE AND OBJECTIVE S 
The purpose of this pi[INVESTIGATOR_474598], usability, and reliability of the BioStamp 
nPoint  system for continuous collection of physiological data in remote (in- home) and healthcare (in-
clinic) settings.  
The primary objective of the clinical investigation is to evaluate the accuracy of  the BioStamp nPoint  
system algorithm measurements and to e valuate t he adhesion (reliability) of the Sensor s. 
 
Safety and tolerability will be further  assessed via a follow -up telephone call.   
4.0 STUDY ENDPOINTS  
4.1 Effectiveness  Endpoints  
The effectiveness endpoints for this study are the various types of measurements made by [CONTACT_474628]. All effectiveness endpoints to be statistical ly summarized will be collected 
using the BioStamp nPoint during in clinic supervised use.  The effectiveness endpoints are as 
follows:  
 
o Heart Rate (bpm)  
o Heart Rate Variability (RMSSD3 (msec) and L F/HF Ratio4) 
o Respi[INVESTIGATOR_1516] (average respi[INVESTIGATOR_1487])  
o Activity Classification (activities –  sleep, standing, sitting, lying, walking and other)  
o Activity Parameters - total step counts in a [ADDRESS_608194]  
o Sleep (sleep onset time (hours, minutes, and seconds), sleep wake time (hours, minutes, 
and seconds))  
o Posture Classification (sleep posture, stationary posture standing, stationary posture 
sitting)  
 
For each endpoint, the BioStamp nPoint  measurements wi ll be compared to a similar FDA -cleared  
measurement device, other measurement devices, or independent observer  measurements.  The 
FDA-cleared measurement devices used as comparators for this study are the Actiheart heart rate 
reference device and the Capnostream portable respi[INVESTIGATOR_172655].  
 
Table 1 displays the comparator method for each endpoint category.  
 
Table 1: Endpoint Variable Group and Measurement Comparator  
Index  Endpoint Variable Group  Measurement Comparator  
1 Heart Rate  Actiheart Device  
2 Heart Rate Variability  Actiheart Device  
3 Respi[INVESTIGATOR_474599]  
4 Activity Classification  Independent Observer  
5 Activity Parameters  Manual Step Counting Device  
6 Sleep Parameters  Independent Observer  
7 Posture  Independent Observer  
 
                                                 
 
3 RMSSD: root -mean- square of successive difference of the time intervals between successive heartbeats.  
4 LF/HF ratio: the ratio of power in the low -frequency (LF, 0.04- 0.15 Hz) and high- frequency (HF, 0.15- 0.4 Hz) bands of heart rate 
variability in the frequency domain.  
   
 
 
 
Protocol: MC10- PTL-103, Revision 00  16 
Confidential  
Individual independent observers will receive training on the operation of all devices and 
execution of the study protocol before the enrollment of any subjects.   
 
For heart rate and heart rate variability, the v alues collected will be the one minute average heart 
rate, the one minute RMSSD and the five- minute LF/HF ratio from the BioStamp nPoint  and the 
one minute average heart rate, RMSSD and five minute L F/HF ratio from the Actiheart device on 
each of six recor ding times for each subject.  Two readings will be taken while the subject is at 
rest, two while exercising and two while lying down.  
 
For respi[INVESTIGATOR_1487], the average sleep  respi[INVESTIGATOR_474600].   
 
For the activity classification variable, each su bject will be presented with five tasks (standing, 
sitting, lying, walking and stationary bike riding) in varied order and the activity classification will 
be recorded by [CONTACT_474629].  This procedure will be 
repeated five times for each subject.  
 
For the exercise parameter number of steps taken, the number of steps taken by [CONTACT_474630] a [ADDRESS_608195] will be recorded using both the BioStamp nPoint and a simple step 
counting device.  
 
For the sleep parameters sleep onset time and wake time, the BioStamp nPoint values and 
independent observer values will be collected on each night at the study site.   
 
Posture classification variables will be analyzed separately for each type of posture activity (sleep 
positions, stationary posture standing and stationary posture sitting). For a given posture activity, 
the posture classification will be recorded by [CONTACT_474631]- truth posture for each subject.  Since sleep position and 
lying posture are identical, this variable will be assessed from awake subjects to ensure that all 
postures are represented. Each repeat will generate 5 independent observations of posture. The 
posture cl assifications for each posture classification variable are given in Table 2. 
Table 2: Posture Variable and Classification  
Index  Posture Variable  Posture Classification  
[ADDRESS_608196] following 24 hours of 
continuous wear.  The adhesion rating scale (Table 3) is as follows:  
 
Table 3: Sensor Adhesion Rating Scale  
Score  Rating  Description  
0 = ≥90% adhered  essentia lly no Sensor lift off the skin  
1 = ≥75% to <90% adhered  some edges only of the Sensor lifting off the 
skin 
2 = ≥50% to <75% adhered  less than half of the Sensor lifting off the skin  
3 = >0% to <50% adhered but not 
detached  more than half of the Sensor lifting  off the skin 
without falling off  
4 = 0% adhered – Sensor detached  Sensor completely off the skin  
   
 
 
 
Protocol: MC10- PTL-103, Revision [ADDRESS_608197] questionnaire.  
 
4.2 Safety 
All adverse events (AEs) reported during the evaluation period will be collected and summarized.  
Serious AEs (SAEs) will be reported in accordance with US Code of Federal Regulation 
requirements.  
5.[ADDRESS_608198] as shown in Figure 2.  
Identification as well as t raceability for each investigational and reference device at the study site will be 
maintained by  [CONTACT_309414].  
 
The Actiheart ( K052489, CamNtech Inc.,  Cambridge, [LOCATION_006] ), used here as the Heart Rate Reference 
device,  is a commercially -available, FDA -cleared, chest -worn monitoring device that records heart rate, 
Inter-Beat-Interval (IBI), and physical activity.  It is designed for calculating and measuring h eart rate and 
Energy Expenditure in free living.  The Actiheart has two clips which attach directly to standard ECG 
electrodes. Usually one electrode is adhered at V1 or V2 (4th intercostal) and the second electrode is 
placed approximately 10cm away on the left side at V4 or V5, although this placement can be adjusted to 
be more comfortable for the subject. The number of R -waves detected is recorded, and an internal 
accelerometer senses the frequency and intensity of the subject's torso movements.  
 
The Capnostream Portable Respi[INVESTIGATOR_140658]  (K150272, Medtronic Inc.,  Dublin, IE ) used here as the 
Respi[INVESTIGATOR_474601], is a commercially -available, FDA -approved, bedside , combined  
capnography/pulse oximetry  monitor, capable of providing a complete pi[INVESTIGATOR_474602] a subject ’s: 
 
• End tidal carbon dioxide (etCO2) -  level of carbon dioxide in exhaled breath.  
• Respi[INVESTIGATOR_697] (RR).  
• Fractional inspi[INVESTIGATOR_307028] (FiCO2) -  level of carbon dioxi de present during inhalation.  
• Oxygen saturation (SpO2).  
• Pulse rate (PR).  
 
It is intended to provide professionally trained health car e providers the continuous, non- invasive 
measurement and monitoring of carbon dioxide concentration of the expi[INVESTIGATOR_474603], and for the continuous non- invasive monitoring of functional oxygen saturation of arterial 
hemoglobin (SpO2 and pulse rate).    
 
Additionally, a commercially -available manual “tally” counter will be used for counting steps.  
 
   
 
 
 
Protocol: MC10- PTL-103, Revision 00  18 
Confidential  
Table 4: Devices for Study Activities  
Materials  Purpose  Supervised  Remote  
MC10 BioStamp nPoint  System     
Sensors  Investigational device  X X 
Link Hub  Investigational device  X X 
Adhesives  Investigational device  X X 
Adhesive Applicator  Investigational device  X X 
Mobile Phone with Link App  Investigational device  X X 
Actiheart (C amNtech Inc. ) with electrodes  Reference device:  
Heart Rate (HR),  
Heart Rate Variability (HRV)  X X 
Capnostream 35 Portable Respi[INVESTIGATOR_474604] (Medtronic Inc. ) with nasal cannula  Reference device:  
Respi[INVESTIGATOR_26452]  X - 
Manual step counter  Reference device:  
Step Counting X - 
 
 
 BioStamp nPoint Sensor  
 Heart Rate Reference Device  
 Respi[INVESTIGATOR_474605] 2: Anatomical Locations for Investigational and Reference Devices  
 
 
 
 
 
 
 

   
 
 
 
Protocol: MC10- PTL-103, Revision 00  19 
Confidential  
6.0 STUDY DESIGN  
The study design is a non-significant risk, open- label, prospective non- randomized clinical investigation 
designed to validate the accuracy of the various physiological par ameters that the MC10 Sensors acquire 
and the system processes , and  to validate the performance of the Sensor skin adhesive.  The study will 
be conducted at a single site in the [LOCATION_002].   
 
Figure 3: Study Design Flow Chart 
6.1 Study Duration  
One supervised session of approximately four hours, with observation periods throughout  and two 
night -time sleep periods ; thus a total evaluation duration of approximately [ADDRESS_608199]-sensor 
removal.  

   
 
 
 
Protocol: MC10- PTL-103, Revision 00  20 
Confidential  
6.2 Schedule of Events  
The evaluation period includes (refer to Section 4.1) clinician observed s upervised testing. Subjects 
will wear a total of four BioStamp nPoint Sensor s for this study; chest, thigh, shank, and forearm, and 
the BioStamp nPoint  system will be con figured, using only the chest and thigh Sensor s, to measure 
and compute algorithm outputs.  
In addition to the algorithm determinate Sensor  locations, the shank and forearm Sensor s (no sensor 
data will be collected) will be utilized in combination with the chest and thigh locations to validate the 
Sensor adhesion performance.  The study is designed to capture supervised,  observed 
measurements, as well as two  nights of sleep in in clinic supervised setting .  
 
  
   
 
 
 
Protocol: MC10- PTL-103, Revision 00  21 
Confidential  
 
Table 5: Schedule of Events  
 
Activities    Screening 
Period  Evaluation Period  Safety  
Clinic  Clinic  Clinic  Clinic  Follow -Up 
Visit  1 1 or 2  1 or 2  2 or 3  2 or 3  Telephone  
Day -60 to 0  0 1 1 2 3-5 
Screening & Enrollment Activities            
Informed Consent  X      Screening survey (demographics, medical 
history , etc. ) X      
Baseline assessment (weight, Fitzpatrick , 
medical history , location irritation ) X X     
Urine pregnancy and drug screen  X X     
Sensor Application        
Application of Functional MC10 Sensors by 
[CONTACT_9142]   X     
Application of Non -functional MC10 Sensors by 
[CONTACT_9142]   X     
Adhesion application assessment   X X    
Application of Functional MC10 Sensors by 
[CONTACT_27720]    X    
Application of Heart Rate Reference Device  by 
[CONTACT_30223]   X     
Application of Respi[INVESTIGATOR_474606]   X  X   
Prescribed Activities (Supervised)        
Activity Classification Activities   X     Heart Rate Activities   X     
Subject training    X    
Overnight sleep   X  X   
Prescribed Activities (Remote)    X    
Time of Removal Assessments  
(MC10, Heart Rate Reference Device)        
Adhesion assessment    X  X  Removal pain assessment    X  X  Skin irritation assessment    X  X  Sensor Removal        Removal of Respi[INVESTIGATOR_474606]    X  X  
Removal of MC10 Sensors by c linician    X    
Clean MC10 Sensors by [CONTACT_30223]    X    
Removal of MC10 Sensors by [CONTACT_27720]      X  
Clean MC10 Sensors by [CONTACT_27720]      X  
Removal of Heart Rate Reference Device  by 
[CONTACT_30223]      X  
Usability Survey    X  X  Data Transfer        MC10 Sensor data transfer    X  X  Respi[INVESTIGATOR_474607]    X  X  Heart Rate Reference Device data transfer      X  Return sensors to investigators      X  Safety follow -up call       X 
Recording of adverse events   X X X X X 
 
  
   
 
 
 
Protocol: MC10- PTL-103, Revision [ADDRESS_608200] no exclusion criteria.  
Reasons for screening failure(s) will be documented.    
7.1 Number of Subjects  
Minimally, t wenty -five (25 ) healthy subjects  (defined as people who do not have the condition or 
related conditions or symptoms being studied to participate in that study; s ee also “Accepts Healthy 
Volunteers”  on ClinicalTrials.gov)  minimally will be enrolled in the study.   
7.1.[ADDRESS_608201] meet all of the following criteria to be eligible for participation in the study:  
1. Male or female volunteers, at least 18 years  of age at the time of screening visit;  
2. Fluent in English;  
3. The subject is willing and physically able to comply with the protocol specified evaluations ; 
4. Subject is  willing and is cognitively able to sign informed consent  
7.1.[ADDRESS_608202] be excluded from participation in this study if any of the following criteria are met:  
1. Pregnancy ; 
2. Positive urine drug scree n 
3. History of active (clinically significant) skin disorders ; 
4. History of allergic response to silicones or adhesives ; 
5. Subjects with electronic implants of any kind (e.g. pacemaker)  
6. History of sleep disorders or self -reported insomnia or other sleep conditions ; 
7. Broken, damaged or irritated skin or rashes near the sensor application sites ; 
8. Subjects that are MC10 employees or shareholders, or a spouse or child of an MC10 
employee or shareholder ; 
9. Subjects who are physically or cognitively unable to normally perform activities of daily living, 
assessed  at the discretion of the investigator.  
8.0 STUDY PROCEDURES  & ASSESSMENTS 
The visit schedule, study procedures, and assessments are presented in the Study Design Flow Chart  
(Figure 3) and the Schedule of Events ( Table 5).  Site pe rsonnel will be instructed via training conducted 
by [CONTACT_212281]10 of the investigational device and reference devices protocol specific operation and use and will 
be documented and approved by [CONTACT_212281]10 via a verification form.  
 
8.[ADDRESS_608203] 
traceability and facilitate subsequent data management and analysis . Study site staff will be  trained  
on the proper configuration, application, and use of the reference devices that are presented in 
Section 5.0 per their associated Instructions for Use as they pertain to the metrics required to fulfil the 
study objectives . 
   
 
 
 
Protocol: MC10- PTL-103, Revision [ADDRESS_608204] Screening/Enrollment Log.  At a minimum, this log is faxed (or emailed) to 
the Sponsor each week.  S ite will also maintain a Subjec t ID List in the PI’s records ensuring that  
subjects may be identified in case of product recalls or safety issues.  
 
Any potential subjects who are pre- screened can be added to the log by [CONTACT_474632]. Those who sign the ICF will be assigned a five- digit sequen tial number. The 
first two digits will represent the site number (i.e., 01) and the remaining three digits are a sequential 
patient number (i.e., 001, 002, 003, etc.). Therefore, the fourth subject screened at site number one 
will be Subject #[ZIP_CODE].  
8.[ADDRESS_608205]’s identifier th roughout the study.   A Screening/Enrollment Log will be maintained by [CONTACT_474633], in order to maintain a cumulative tracking of all screened subject s.  
8.[ADDRESS_608206] ’s informed consent.   
8.6 Screening and Baseline (Day 0) Evaluation  
The following evaluations are required at the time of subject  screening/baseline:  
1. Urine pregnancy test  and drug screen;  
2. Medical History & Current Status – skin disorders;  
3. Medical History & Current Status –  allergies;  
4. Medical History & Current Status –  electronic implants;  
5. Medical History & Current Status – insomnia/sleep conditions ; 
6. Evaluation of application sites for broken, damaged, or ir ritated skin or rashes;  
7. MC10 affiliation survey/question  
8. Demographics Information:  Age, Gender, Height, Weight, Fitzpatrick skin type.  
 
Source documents relat ed to screening activities will be filled out for all screened subjects.  
8.[ADDRESS_608207] may only exit the study as a withdrawal (not a screen failure).  The reason 
   
 
 
 
Protocol: MC10- PTL-103, Revision 00  24 
Confidential  
for withdrawal will be documented by [CONTACT_474634].  All records of enrolled but 
withdrawn subjects will be retained as part of the study.  
 
8.8 Study  Assessments – In Clinic – Visit 1 (Supervised ) 
During the supervised evaluation period, subjects wil l arrive at the study clinic on Day 0.  After 
admission to the clinic, but before the start of the evaluation period, a skin inspection of planned 
sensor application sites will be conducted.   
The clinical site staff will provision  Sensors, a Link Hub, and a Link App phone to the subject  using 
the Link App. They will then apply four Sensors  and reference device sensors  to the subject . Two of 
these Sensors will be applied following instructions on the Link App; the other two are for assessing 
adhesion only, and will be applied following written instructions .  
Site staff will  then initiate and monitor the prescribed activities for the supervised  portion of the study.  
The prescribed acti vities consist of general tasks:  sitting, standing, lying down, leaning, walking,  and 
biking .  The site staff will instruct the subject throughout the evaluation.  
For each of the prescribed activities, the site staff will start an annotation in the MC10 Link App to 
indicate that the subject is starting to perform an activity and will stop the annotation after a specific 
period of time when the subject has completed the activity.  Each annotation will be tagged with a 
letter and a number. The letter and number used for the annotation of each activity performed will be 
noted on the CRF. The followi ng activities will be conducted as prescribed in sections  8.8.2  - 8.8.7.  
8.8.1  Application of the Heart Rate Reference Device  
The Heart Rate Reference Device will be applied as described in Section 5.0 , following the 
manufacturer’s IFU , 30 minutes prior to the start of study activities to allow for  sensor to body 
continuity.  Heart rate will be monitored throughout the study including during the activities in 
Table 7 and Table 8.  
8.8.2  BioStamp nPoint Sensor Application  
The cli nician will apply  sensors (turned off, no signal data) to the shank and forearm, and 
functional sensors to the chest , aligned to [ADDRESS_608208] with the battery 
end pointed upwards  (left nipple to right shoulder) , and thigh, aligned vertically on the central 
thigh with the battery end pointed upwards , as prescribed by [CONTACT_474635].  
MC10 Sensor adhesion will be assessed ( refer to Table 3).  The activities in Table 6 will be 
conducted and annotated following the guided prompts provided by [CONTACT_474636].  
 
Table 6: Application  Activities  
Item Activity  Description  Time  Repetitions  
[ADDRESS_608209] stands still in an upright vertical position  10 s 1 
 
8.8.3  Activity Classification  
The activities in Table 7 will be conducted as prescribed, in a variable order,  and will be 
annotated by [CONTACT_474637]. 
The particular activity performed for a given annotation will be noted on the CRF.  This set of 
activities will be performed 5 times  in a random order each time, as listed in the Repetitions 
column of Table 7.  
   
 
 
 
Protocol: MC10- PTL-103, Revision 00  25 
Confidential  
Table 7: Activity Classification Activities  
Item Activity  Description  Time  Repetitions  Metric  
[ADDRESS_608210] is standing upright, start the activity.  1 min  5 ADL Classifier –  Standing 
HR/HRV – Resting 
[ADDRESS_608211] is sitting, start the activity.  1 min 5 ADL Classifier –  Sitting  
HR/HRV – Resting 
[ADDRESS_608212] is lying in a supi[INVESTIGATOR_2547], start the 
activity.  1 min  5 ADL Lying 
HR/HRV – Resting 
[ADDRESS_608213] is in position, start 
the activity.  1 min  5 Posture 
HR/HRV – Resting 
[ADDRESS_608214] is in 
position, start the activity.  1 min  5 Posture 
HR/HRV – Resting 
[ADDRESS_608215] is in 
position, start the activity.  1 min  5 Posture 
HR/HRV – Resting 
[ADDRESS_608216] is in 
position, start the activity.  1 min  5 Posture 
HR/HRV – Resting 
[ADDRESS_608217] is in position, 
start the activity.  1 min  5 Posture 
HR/HRV – Resting 
[ADDRESS_608218] is in position, start the activity.  1 min  5 Posture 
HR/HRV – Resting 
[ADDRESS_608219] is in position, start the 
activity.  1 min  5 Posture 
HR/HRV – Resting 
[ADDRESS_608220] is in position, start the 
activity.  1 min 5 Posture 
HR/HRV – Resting 
[ADDRESS_608221] is in position, start the 
activity.  1 min  5 Posture 
HR/HRV – Resting 
[ADDRESS_608222] is in position, start the 
activity.  1 min  5 Posture 
HR/HRV – Resting 
[ADDRESS_608223] is in position, start the activity.  1 min  5 Sleep posture  
HR/HRV – Resting  
[ADDRESS_608224] is in position, start the 
activity.  1 min  5 Sleep posture  
HR/HRV – Resting 
[ADDRESS_608225] is in position, start the 
activity.  1 min  5 Sleep posture  
HR/HRV – Resting 
[ADDRESS_608226] is in position, start the 
activity.  1 min  5 Sleep posture  
HR/HRV – Resting 
   
 
 
 
Protocol: MC10- PTL-103, Revision [ADDRESS_608227]-activity assessment: How many total 
steps did the subject take during the walking 
activity?  6 min  5 ADL Classifier –  Walking 
Pedometer  
HR/HRV – Moving 
[ADDRESS_608228] 
starts  walking, start the activity.  1 min 5 ADL Classifier –  Walking 
 
[ADDRESS_608229] starts biking, start the activity.  8 min 5 ADL Classifier –  Other  
HR/HRV – Moving 
8.8.[ADDRESS_608230] performance to ensure that the activities are 
properly annotated.    
Table 8: Heart Rate Activities  
Item Activity  Description  Time  
(minimum)  Repetitions  Metric  
[ADDRESS_608231] 2, 
up to 4  HR/HRV – 
Resting  
[ADDRESS_608232] 2, 
up to 4  HR/HRV – 
Moving  
[ADDRESS_608233] 2, 
up to 4  HR/HRV – 
Moving  
 
8.8.2  Application of the Respi[INVESTIGATOR_474608] 5.0, following the 
manufacturer’s IFU , prior to the subject going to bed.  
8.8.[ADDRESS_608234] goes to bed (lights out) and arises from bed (woken by [CONTACT_6624]) , the sleep 
onset time and wake time will be recorded by [CONTACT_474638]. Su bjects will be observed 
throughout the night to annotate  on the CRF  any periods of wakefulness between these times.  
8.8.[ADDRESS_608235]’s night of sleep . 
8.8.5  Removal of the Respi[INVESTIGATOR_474609] 5.0, following the 
manufacturer’s IFU after the subject arises from bed.  
 
8.8.[ADDRESS_608236] set of sensors, and after 24 hours of sensor wear for the 
four body locations, clinical staff will rate the skin adhesion using a 5- point scale (0 -4, refer to 
Table 3)7 .  
 
Adhesion will be scored by [CONTACT_474639].  
 
   
 
 
 
Protocol: MC10- PTL-103, Revision [ADDRESS_608237], thigh, shank, and 
forearm as prescribed by [CONTACT_474635].  
8.8.8  Safety and Tolerability Assessment  
Safety and tolerability will be assessed  immediately by [CONTACT_474640] ’s removal 
based on qualitative (visual observations) assessments of skin redness .  
 
Skin irritation will be assessed on a 0 to 3 scale based on native assessm ents (visual 
observations) of skin irritation using the following scale8 (Table 9). 
 
 
Table 9: Irritation  Rating Scale  
Score  Rating  Description  
0 No reaction  --- 
1 Weakly positive reaction  usually characterized by [CONTACT_474641]/or 
dryness across most of the treat ment site  
[ADDRESS_608238] erythema or dryness, possibly 
spreading beyond the treatment site  
3 Strongly positive reaction  strong and  often spreading erythema with 
edema and/or eschar formation  
 
8.8.[ADDRESS_608239] and thigh sensors 
using the Link App.  The sensors will not be used again.  
 
Site staff will download t he Heart R ate Reference D evice data to a dedicated study computer  at 
the end of the wear period using the manufacturer’s proprietary software per the instructions for 
use.  
 
Site staff will download t he Respi[INVESTIGATOR_474610] D evice data after each night of sleep to a USB 
stick following the manufacturer ’s instru ctions for use.  
 
8.8.[ADDRESS_608240] Training  – Remote Kit  
The subject will be trained on the BioStamp nPoint  system subject IFU and the Link App 
operations to be performed under observation, defined in Section 8.9. While observed by [CONTACT_984], t he subject will then apply the sensors to the chest and thigh using the Link App, and  will 
conduct and annotate the activities in Table [ADDRESS_608241] 
through re- applying any S ensors with a non- zero score for up to two applications .  If two non- zero 
scores are noted, the clinician should then apply the Sensor.  
8.9 Study Assessments – Remote (Unobserved) 
After the completion of the supervised evaluation period, subject training,  and replacement of 
BioStamp nPoint  sensors  on Day 1,  the subject will remain in the clinic , where they will continue to 
wear the BioStamp nPoint  system and the Heart Rate Reference Device  and execute Table 8 
activit ies.  
   
 
 
 
Protocol: MC10- PTL-103, Revision 00  28 
Confidential  
8.10 Study Assessments – In Clinic – Visit 2 ( Supervised ) 
On the same day  (Day 1) , the subject will go to bed.  Upon waking, clinical site staff will observe the 
subject removing, cleaning, synchronizing, and beginning to recharge the BioStamp nPoint  sensors.  
Sensor s afety  and tolerability will then be assessed.   
8.10.[ADDRESS_608242] goes to bed (lights out) and arises from bed (woken by [CONTACT_6624])  the sleep 
onset time and wake time will be recorded by [CONTACT_474638]. Subjects will be observed 
throughout the night to annotate on the CRF any periods of wakefulness between these times  
8.10.[ADDRESS_608243] as described in Section 5.0, following the manufacturer’s IFU.  Respi[INVESTIGATOR_474611]’s  night of sleep.  After the subject wakes, 
the Respi[INVESTIGATOR_474612] l be removed as prescribed in Section 5.0, following the 
manufacturer’s IFU.  
8.10.[ADDRESS_608244] and thigh , and will clean them, synchronize  the recorded data, and begin to recharge 
the sensors  as prescribed by [CONTACT_474635].  
8.10.4  Safety and Tolerability Assessment  
Safety and tolerabil ity will be assessed  immediately by [CONTACT_474640] ’s removal 
based on qualitative (visual observations) assessments of skin redness level.  
 
Skin irritation will be assessed on a 0 to 3 scale based on native assessm ents (visual 
observations) of the skin sensor locations using the scale9 located in Table 9. 
 
8.10.5  Equipment Return  
The Heart Rate Reference Device will be removed. T he subjects will return the provisioned 
equipment ; equipment return will be documented on the Device Accountability Form.  
8.10.[ADDRESS_608245]  Follow -up 
A Safety f ollow -up telephone call will be made between Day  3 and Day 5 to assess for adverse 
events associated with study participation.  
   
 
 
 
Protocol: MC10- PTL-103, Revision [ADDRESS_608246]  Completion  
Completion of the study is defined as:  
1. comple ting the supervised activities ; 
2. wearing the sensors for two days;  
3. returning the s ensors to the coordinators;  
4. completing the usability survey;   
5. completing the follow -up telephone call.  
9.[ADDRESS_608247]  Early Discontinuation / Withdrawal of Subject s 
Subjects are free to withdraw from the study at any time, without prejudice.  Subjects should be 
withdrawn from the study if any of the following events occur:   
1. Subject develops an illness or any other condition or event that would interfere with his/her 
continued participation;    
2. Subject is noncompliant with the study procedures , or unable to continue  in the opi[INVESTIGATOR_684];    
3. Subject withdraws his/her consent;  
4. The Sponsor or a regulatory agency requests withdrawal of the subject.   
Investigators should attempt to obtain information on subjects, in the case of withdrawal or 
discontinuation. For subjects considered as lost to follow -up, the Investigator should make an effort 
(at least [ADDRESS_608248]  on each of 2 separate days ), and document his/her effort (date 
and summary of the phone call in the source documents)  to complete the final evaluation. All results 
of these evaluations and observations, together with a narrative description of the reason(s) for 
discontinuing the subject, must be recorded in the source documents.  The Study Termination Case 
Report Form ( CRF) must document the primary reason for withdrawal or disconti nuation .   
10.0 Risk / Benefit Analysis  
10.[ADDRESS_608249] s are expected to be minimal under this protocol  
and are described in Section 14.5.  
The BioStamp nPoint  system sensor includes  a non- invasive biosensor that is attached to the surface 
of the skin using an adhesive sticker, and is designed to measure movement, heart rate, h eart rate 
variability,  and sleep metrics using embedded accelerometer, gyroscope, and electrodes.  The study 
is designed to assess the system’s ability to capture and analyze movement, heart rate, heart rate 
variability, and sleep.   
This is the first clinical trial for this device.  The study will enroll healthy subjects at one study site in 
the [LOCATION_002].   
The device will not be used in this study as an implant; it will not be used to support or sustain human 
life; it will not be of substantial importance in diagnosing, curing, mitigating, or treating disease, or 
otherwise preventing impairment of human health in this study; and the use in this study will not 
otherwise present a potential for serious risk to the health, saf ety, or welfare of a subject.  H arm 
   
 
 
 
Protocol: MC10- PTL-103, Revision [ADDRESS_608250] the subjects at significant risk.   As indicated in Section 
14.5, s kin irritation is an anticipated risk .  
The BioStamp nPoint  system is Non -Significant Risk under the proposed investigational study based 
on a comprehensive risk analysis per Investigational Device E xemptions, 21 C.F.R. § 812.3(m) 
(2016) and proposed use of the device10.  
10.[ADDRESS_608251] design, testing , and 
through careful labeling and instructions for use. Risks will be further mitigated through selection of 
qualified physicians, appropriate training, and study monitoring ensured by [CONTACT_716]:  
• Investigators who participate in the study will be experienc ed and skilled in collection of 
physiological data . Additionally, investigators, in conjunction with the investigational site, will 
have adequate resources for participation in a clinical study.    
• Each investigator will ensure oversight and approval of the study by [CONTACT_154630]  (IRB)  prior to initiation of the clinical study at his/her investigational site.   
• The investigator and study personnel will be trained on the clinical protocol , investigational 
device and Instructions for Use.   
• Subjects will be carefully evaluated against the inclusion/exclusion criteria prior to entering 
the clinical study to ensure that their diagnosis and medical status are appropriate for 
participation i n the clinical study.   
• Subjects will be monitored throughout the follow -up period as  defined in the study protocol.   
• Any adverse events occurring during the time of the investigational procedure will be closely 
monitored and the subject  shall be followed until resolution or is judged to be chronically 
stable, and any deleterious trends investigated as early as possible.   
11.0 STATISTICAL METHODS  
11.1 Introduction  
The study is a non- significant risk, prospective, non- randomized study of the perfor mance 
characteristics of the BioStamp nPoint device in healthy adult subjects.  Subjects will be enrolled in 
the trial for approximately 48 hours.  The primary objectives of the statistical analyses are to evaluate 
the agreement of the BioStamp nPoint measurements to commonly accepted measurement 
standards.   
A study center is defined as a hospi[INVESTIGATOR_474613].   
11.2 Sample Size  
The sample size of n=25 subjects is sufficient to meet business needs of the Sponsor and is 
comparable to the size of studies with similar devic es.  An additional 5 subjects may be enrolled to 
account for a 20 % dropout rate.   
11.3 Effectiveness Variables  
The effectiveness endpoints for this study are the various types of measurements made by [CONTACT_474628]. All effectiveness endpoints to be statistically summarized will be collected 
using the BioStamp nPoint during the supervised- use phase.  The effectiveness endpoints are as 
follows:  
 
   
 
 
 
Protocol: MC10- PTL-103, Revision 00  31 
Confidential  
o Heart Rate (bpm)  
o Heart Rate Variability (RMSSD5 (msec) and L F/HF Ratio6) 
o Respi[INVESTIGATOR_1516] (average respi[INVESTIGATOR_1487])  
o Activity Classification (activities –  standing, sitting, lying, walking and other)  
o Activity Parameters - total step counts in a [ADDRESS_608252]  
o Sleep (sleep onset time (hours, minutes, and seconds), sleep wake time (hours, minutes, 
and seconds))  
o Posture Classification (sleep posture, stationary posture standing, stationary posture 
sitting)  
 
For each endpoint, the BioStamp nPoint  measurements will be compared to a similar FDA 
approved measurement device, to other basic  or manual  measurement devices , or to 
independent observer measurements.  The FDA approved measurement devices for this study 
are the Actiheart heart rate reference device and the Capnostream portable respi[INVESTIGATOR_172655].  
Table 10 displays the comparator method for each endpoint category.  
Table 10: Endpoint Variable Group and Measurement Comparator  
Index  Endpoint Variable Group  Measurement Comparator  
1 Heart Rate  Actiheart Device  
2 Heart Rate Variability  Actiheart Device  
3 Respi[INVESTIGATOR_474599]  
4 Activity Classification  Independent Observer  
5 Activity Parameters  Manual Step Counting Device  
6 Sleep Parameters  Independent Observer  
7 Posture  Independent Observer  
 
Individual independent observers will receive training on the operation of all devices and 
execution of the study protocol before the enrollment of any subjects.   
 
For heart rate and heart rate variability, the values collected will be the one minute average heart 
rate, the one minute RMSSD , and the five- minute LF/HF ratio from the BioStamp nPoint  and the 
one minute average heart rate, the one minute RMSSD , and five minute L F/HF from the Actiheart 
device on each of six recording times for each subject.  Two readings will be taken while the 
subject is at rest, two while exercising and two while lying down.  These readings will be collected 
during the activities listed in Table [ADDRESS_608253] will be presented with five tasks (standing, 
sitting, lying, walking and stationary bike riding) in varied order and the activity classification will 
be recorded by [CONTACT_474642].  This procedure will be 
repeated five times for each subject.  
 
                                                 
 
5 RMSSD: root -mean- square of successive difference of the time intervals between successive heartbeats.  
6 LF/HF ratio: the ratio of power in the low -frequency (LF, 0.04- 0.15 Hz) and high- frequency (HF, 0.15- 0.4 Hz) bands of heart rate 
variability in the frequency domain.  
   
 
 
 
Protocol: MC10- PTL-103, Revision 00  32 
Confidential  
For the exercise parameter “ number of steps taken” , the number of steps taken by [CONTACT_474630] a [ADDRESS_608254].  
 
For the sleep parameters sleep onset time and wake time, the BioStamp nPoint values and 
independent observer values will be collected on each night  and morning at the study site.   
 
Posture classification variables will be analyzed separately for each type of posture activity (sleep 
positions, stationary posture standing and stationary posture sitting). For a given posture activity, 
the posture classification will be recorded by [CONTACT_474631]- truth posture for each subject. Each repeat will generate 5 
independent observations of posture. The posture classifications for each posture classi fication 
variable are given in Table 11. 
 
 
Table 11: Posture Variable vs Classification  
Index  Posture Variable  Posture Classification  
[ADDRESS_608255] following 24 hours of continuous wear.  The 
adhesion rating scale  is presented in Table 3.  
 
11.4 Analysis Populations  
The following analysis populations will be defined for the study:  
 
• Intent -to-Measure (ITM) Population – The ITM population will consist of all subjects who are 
enrolled in the study and for which the ability of each measurement device to measure the 
subject has been established.  
 
• Safety Population – The safety population will consist of all subjects who are enrolled in the 
study . 
 
The ITM population will be the primary analysis set for all effectiveness analyses.  The safety 
population will be used for the analysis of all safety variables and baseline characteristics.  
11.5 Analysis Subgroups  
There is no subgroup analysis planned for the study.  
11.6 Statistical and Analytical Plans  
11.6.1  Disposition and Demographics  
A table will be constructed with counts and percentages of the number of subjects who were 
screen failures, the number of subjects enrolled in the study, the number of su bjects withdrawn 
from the study before study completion, and the number who completed the study.  For those 
subjects who withdrew before completion of the study, counts and percentages of the reasons for 
withdrawal will be tabulated.   
 
   
 
 
 
Protocol: MC10- PTL-103, Revision 00  33 
Confidential  
The continuous demographic characteristics at screening will be summarized for all subjects in 
the safety population using descriptive statistics (mean, standard deviation, median, minimum, 
maximum, and number of non- missing observations).  The categorical baseline character istics 
will be summarized for the safety population using frequency counts and percentages.  
11.6.2  Effectiveness Endpoint Analyses  
For pairs of measurements collected on the continuous scale (quantitative to quantitative 
comparisons), scatter plots with the 45 de gree line of agreement superimposed will be 
constructed from paired observations from the two sources (BioStamp nPoint vs comparator)  
along with Bland- Altman plots of the data.  The mean absolute error (MAE) and the root -mean-
square error (RMSE) estimates  of agreement will be calculated for each comparison.  The 
standard deviations of each of the agreement measures will also be computed.   
 
For pairs of measurements collected on a categorical scale (qualitative to qualitative 
comparisons), two- way tables of agreement will be constructed for each comparison.  The 
agreement percentage will be computed for each table.  
 
The number and percentage of sensor patches in each category of the adhesion scoring scale 
will be tabulated.  
 
The statistical analyses of the effectiveness data will also be described in the Statistical Analysis 
Plan (SAP) for the study.  The SAP will be written and finalized prior to database lock.    
 
11.6.[ADDRESS_608256] has completed the study, the sum total of analytic outputs from the study will be 
exported from the MC10 Cloud and stored in a read- only archive.  This archive will be entered into 
   
 
 
 
Protocol: MC10- PTL-103, Revision 00  34 
Confidential  
MC10’s Quality system, and a checksum  to uniquely represent this archive w ill be computed.  This 
checksum will be sent for entry into the trial database.  After the checksum has been entered, C TI will 
archive all ground- truth data in a read- only format and compute a checksum  on the resulting archive.  
This checksum will also be entered into the trial database.  CTI will then send the ground- truth data 
archive to MC10 for data extraction and time- alignment.  MC10 will then send the relevant data for 
entry into the trial database and subsequent analysis.  All tools to be used in this process will be 
validated.  
12.[ADDRESS_608257] data will be entered into CRFs and combined with data provided 
from other sources in a validated data system that will reside in the clinical data management 
database.   
Clinical data management will be performed in accordance with applicab le MC10 or their designee’s 
SOPs; data cleaning procedures will be performed with the objective of ensuring all data fields are 
populated, and removing errors and inconsistencies in the data which would otherwise impact the 
analysis and reporting objectives, or the credibility of the final study report.   
The princip al investigator is responsible for the accuracy and completeness of all study 
documentation.  The clinical monitor will collec t the originals and the investigational site shall retain 
the copi[INVESTIGATOR_014].  
12.[ADDRESS_608258]  data and ensure 
compliance with Good Clinical Practice (GCP), clinical protocol and other study requirements. 
Monitoring visits to the clinical site (s) will be made periodically during the study, to ensure that all 
aspects of the current, approved protocol/amendment(s) are followed.  
Prior to the enrollment of any subject in this study, the Monitor and the Investigator will review the 
protocol, the procedure for obtaining informed consent and the procedure for reporting adverse 
events.  On -site and remote monitoring visits will be perf ormed by [CONTACT_35717] . Case report forms will 
be verified against source documentation  and subject compliance will be monitored.  
The Monitor is responsible for ensuring, through personal contact [CONTACT_474643], and that these obligations are being fulfilled throughout the study.  Specifically, 
the Monitor will interact with the site via telephone contact [CONTACT_474644]- site visits to ensure that:  
• Study facilities continue to be acceptable for the conduct of the study  
• Regulatory and study documents are complete and up -to-date  
• The protocol is appropriately followed  
• Protocol amendments have been approved by [CONTACT_474645] (as 
applicable), and the Sponsor has received the approval in writing   
• Qualified subjects are enrolled in a timely manner  
• Accurate, complete, and current records are maintained for all subjects  
   
 
 
 
Protocol: MC10- PTL-103, Revision 00  35 
Confidential  
• The information recorded and submitted to the Sponsor is representative of the subject 
record and other supporting documentation  
• Problems with inconsistent and incomplete data are addressed  
• Accurate, complete, and timely adverse event reports are being made to the Sponsor  
• The Principal Investigator [INVESTIGATOR_474614]   
• Investigational devices are properly stored, dispensed, and accounted for  
13.[ADDRESS_608259] labels and the Instructions for Use 
(IFU) for the operation of the device.  The packaging of the BioStamp nPoint  system will be labeled in 
compliance with 21 CFR Part 812.5.  Each device label will include the wording “Caution – 
Investigational Device.  Limited to Investigational Use” or similar  language.  
13.3 Device Accountability 
Access to investigational devices shall be controlled and used only in the clinical investigation and 
according to the Protocol.  
The Sponsor shall keep records to document the phy sical location of all investigational devices  from 
shipment  (or hand- carried)  to the sites until return or disposal.  
The principal  investigator [INVESTIGATOR_5694], use, 
return, and disposal of the investigational device , which shall include:  
• The date of receipt  
• Identification of each investigational device ( serial and or lot number)  
• The date or dates of use 
• Subject identification  
• Date of return of unused, expi[INVESTIGATOR_5697], or malfunctioning investigational device, if applicable  
The Investigator must explain in writing the reasons for any discrepancy noted in device 
accountability.  
14.0 ADVERSE EVENTS 
14.1 Definitions  
Adverse events will be recorded and documented throughout the duration of the study.  In this study, 
adverse events will be defined and classified per ISO [ZIP_CODE]:2011(E) Clinical Investigations of 
Medical Devices in Human Subjects  - Good Clinical Practice and all applicable internal Sponsor 
procedures ; see Table 12 for details .  Per ISO [ZIP_CODE]:2011(F), “ADE” will include any AE related to 
the investigational device, as well as any AE related to study design.  
Table 12: Adverse Eve nt Definitions  
Adverse Event  Non-device related  Device - or procedure -related  
Non-serious  Adverse Event  Adverse Device Effect (ADE)  
Serious  Serious Adverse Event  Serious Adverse Device Effect (SADE)  
Anticipated  Unanticipated  
Anticipated Serious Adverse Device 
Effect  Unanticipated Serious Adverse 
Device Effect  
   
 
 
 
Protocol: MC10- PTL-103, Revision 00  36 
Confidential  
 
14.1.1  Adverse Event s 
Adverse events (AE) are any untoward medical occurrence, unintended disease or injury, or 
untoward clinical signs (including abnormal laboratory findings) in which subjects,  users or other 
persons, whether or not related to the investigational medical device.  
All adverse events, regardless of relationship to the device, must be recorded, as applicable, on 
the case report forms provided. Adverse events that occur during this s tudy should be treated by 
[CONTACT_214717],  which will protect the life and safety of the subject s. 
Adverse events shall be assessed and documented at the time of the procedure and at all study 
follow -up visits. Each investigator shall provide source documentation as requested by [CONTACT_214718].  
14.1.2  Serio us Adverse Event s 
An adverse event is considered a Serious  Adverse Event (SAE) that  
a. led to death  
b. led to a serious deterioration in the health of the subject, that either resulted in  
1) a life-threatening illness or injury, or  
2) a permanent impairment of a body structure or a body function, or   
3) in - patient hospi[INVESTIGATOR_1081], or   
4) a medical or surgical intervention to prevent permanent life-threatening illness or injury 
or permanent impairment to body structure or a body function.  
c. led to fetal distress, fetal death or a congenital ab normality  
14.1.[ADDRESS_608260] (U SADE) is defined as any serious  adverse 
effect on health or safety or any life- threatening problem or death caused by, or associated with, 
a device, if that effect, problem, or death were not previously identified in nature, severity, or 
degree of incidence in the investigational plan or labeling , or any other unanticipated serious 
problem associated with a device that relates to the rights, safety, or welfare of subjects.   
14.[ADDRESS_608261] becoming aware of the event using the appropriate CRF. All other 
adverse events (i.e. other than serious adverse events or unanticipated adverse device effects) must 
be recorded on the appropriate CRFs. The Medical Monitor will contact [CONTACT_474646], if required.  
For an y adverse event that is ongoing at the time of the initial report, periodic follow -up information is 
required until the adverse event is resolved or is judged to be chronically stable.  The site should 
submit relevant follow -up information related to the adverse event as soon as it is available.  
Depending upon the nature and seriousness of the adverse event, the Medical Monitor may request 
the Investigator to provide copi[INVESTIGATOR_9238]’s medical records (such as the subject ’s laboratory 
tests and hospi[INVESTIGATOR_1097], Investigator summaries, etc.) to document the adverse event.  The 
Medical Monitor is available to respond to any medical issues that arise during the conduct of this 
   
 
 
 
Protocol: MC10- PTL-103, Revision [ADDRESS_608262] provide the following information:  
• Date of onset  
• Nature  
• Severity 
• Duration / date of resolution 
• Outcome  
• Relationship to investigational device  
• Other relevant information 
14.3.[ADDRESS_608263] determine the severity of the adverse event according to the following 
definitions:  
• Mild - The adverse event is noticeable to the subject, but does not interfere with routine 
activity; the symptoms are easily tolerated and transient in nature.  
• Moderate  – The adverse event interferes with routine activity but responds to 
symptomatic therapy or r est; the symptoms are poorly tolerated and sustained.  
• Severe  – The adverse event significantly limits the subject’s ability to perform routine 
activities despi[INVESTIGATOR_4795].  The adverse event requires medical or surgical 
treatment or results in hospi[INVESTIGATOR_059].  
• Life-Threatening – The subject is at immediate risk of death.  
14.3.[ADDRESS_608264] provide an assessment of the adverse event association of device 
relatedness according to the following definitions:  
• Definite  – The adv erse event is clearly related to the investigational device: the event 
has a temporal relationship to the investigational device, follows a known pattern of 
response, or is otherwise logically related to the investigational device, and no alternative 
cause is present.  
• Probable (Likely)  – The adverse event is likely related to the investigational device: the 
event has a temporal relationship to the investigational device, follows a known or 
suspected pattern of response, or is otherwise logically related to the investigational 
device, but an alternative cause may be present.  
• Possible (Unlikely)  – The adverse event is unlikely related to the investigational device: 
the event does not follow a clear temporal relationship to the investigational device or 
   
 
 
 
Protocol: MC10- PTL-103, Revision [ADDRESS_608265]’s clinical state or other modes of therapy.  
• Not Related  – The adverse event is clearly not related to the investigational device: the 
event has no temporal or other relat ionship to the administration of the investigational 
device follows  no known or suspected pattern of response, and an alternative cause is 
present.  
• Unknown  – Unable to determine the relationship based on all available information.  
14.[ADDRESS_608266] to its identity, quality, 
durability, reliability, safety or performance (includes malfunctions, use errors, and inadequate 
labeling).  Sponsor will assess all device deficiencies that c ould have led to a serious adverse device 
effect for potential regulatory reporting requirements.   
In the event of a suspected malfunction or device deficiency, the investigational device shall be 
returned to the Sponsor for analysis. Instructions for ret urning the investigational device will be 
provided by [CONTACT_456].  
14.5 Anticipated Device Related Effects  
As a dermal application, the BioStamp nPoint sensors  may cause mild skin irritation/reactions;  
however , these reactions can be moderate to severe. These s kin reactions (such as macular 
erythema,  allergic reactions, inflammation, pain, skin irritation/damage) are expected to be minor 
because  the patient contact [CONTACT_474647]. However, these skin reactions may manifest to a more severe form (such as  burning, 
blistering, and intense redness). If an anticipated device related effect manifests in an 
uncharacteristic or  unusual manner (e.g., an effect occurs with greater severity or specific ity from that 
mentioned above), the effect should no longer be considered anticipated.  
 
Any anticipated device effect that results in a SAE or SADE must be reported to MC10 in accordance 
with the procedures outlined in Section 14.3.  
15.[ADDRESS_608267]’s  participation.  Subjects are instructed to report any 
adverse effects or concerns immediately; in addition, we will directly inquire as to advers e events at the 
exit interview.  Subjects are free to terminate participation in the study at any time.  No formal Data Safety 
Monitoring Board is planned.  
  
Adverse events and unanticipated problems involving risks to subjects or others will be reviewed by [CONTACT_28824], who will judge whether event(s) were expected or not, or related or not to  the study.  
In addition, the investigator will also determine the best course of action to ensure subject safety.  
 
MC10 will be responsible for receiving SAE reports from the study site, gathering information from the 
study site concerning these Serious A dverse Events, reporting these SAEs to FDA on the proper forms 
within the time constraints specified in the CFR , and following up with the study site until the SAE 
resolves.   
16.0 STUDY ADMINISTRATION  
16.1 Statement of Compliance  
The clinical investigations will b e in accordance with the ethical principles of the Declaration of 
Helsinki ( 64th WMA General Assembly, Fortaleza, Brazil  October 20 13), ISO [ZIP_CODE]:2011 and ICH-
GCP Guidelines . 
   
 
 
 
Protocol: MC10- PTL-103, Revision 00  39 
Confidential  
• The clinical investigation shall not c ommence until approval by [CONTACT_1201] .   
• Any additional requirements imposed by [CONTACT_474648].  
• The Sponsor shall maintain a Clinical Trial Liability Policy with an insurance company.  
16.2 IRB Approval  
The study protocol  shall be reviewed and approved by [CONTACT_31691]’s IRB or a contract IRB if the 
participating institution allows,  prior to subject  enrollment.  The Sponsor must review any proposed 
changes to the investigational plan prior to implementation.  The Sponsor and the IRB must approve 
significant changes to the investigational plan in writing by [INVESTIGATOR_401947].  A significant 
change is one which may increase the risk or present a new risk to a subject , or which may adversely 
affect the scientific validity of the study.  
Prior to shipment of investigational devices, a signed copy of the IRB  approval letter identifying the 
clinical study and investigational site is r equired to be submitted to the Sponsor .  Investigators are 
responsible for obtaining and maintaining annual renewal of  the study by [CONTACT_11577]  (or according to 
renewal schedule imposed by [CONTACT_1201] ).  Evidence of renewal and continued IRB approval must be 
provided to the Sponsor accordingly.  
16.[ADDRESS_608268]’s understanding and autonomy by [CONTACT_474649]/her own words.  
Once that step is completed, consent will be able to be give n by [CONTACT_423]’s signing the consent 
form. A copy of the consent form will be given to all consented participants.   
Signed subject consent forms must be retained in the study files by [CONTACT_737], and available for 
review by [CONTACT_1052]/or regu latory agencies, as applicable.  
The informed consent form and any other written information provided to subjects will be revised 
whenever important new information becomes available, or if there is an amendment to the protocol 
which necessitates a change to the content of subject information and/or to the consent form.  The 
Investigator will inform the subject of changes in a timely manner, and will ask the subject  to confirm 
his/her continuation in the study by [CONTACT_2960] a revised consent form.   
Any revise d informed consent form and other written information provided to subjects must receive 
IRB, Sponsor, and regulatory agency approval, as applicable.  
16.[ADDRESS_608269] be approved by [CONTACT_474650]. However, in situations where the amendment is regarding safety issues and there is 
   
 
 
 
Protocol: MC10- PTL-103, Revision [ADDRESS_608270]  benefit/risk ratio (e.g., editorial changes for 
clarity) may be made without any further approvals.  
16.5 Protocol Deviations /Violations  and Medical Emergencies  
A protocol deviation or violation is a failure to comply with the requirements of the clinical study as 
specified in the protocol.  Examples of protocol deviations include late visits, missed visits, required 
follow -up testing not completed.  An example of a protocol violation includes enrollment of a study 
subject who fails to meet inclusion/exclusion criteria as specified in the protocol.  Each investigator 
shall conduct this clinical study in accordance with the study protocol and any conditions required by 
[CONTACT_3488] . 
Deviations /violations  from clinical protocol requirements will be reviewed and evaluated on an 
ongoing basis and, as necessary, appropriate corrective actions put into place.  The Sponsor  accepts 
the right of the Investigator to deviate from the protocol in an emergency when necessary to 
safeguard the life or the physical well-being of a study subject . Such deviations  must be reported 
within [ADDRESS_608271] be provided to 
the Sponsor : 
• Signed protocol/protocol amendments  
• Signed and dated Investigator A greement(s)  
• A copy of the written IRB  approval of the protocol  
• A copy of the written IRB  approval of the Informed Consent Form   
• Signed and dated Curriculum Vitae of the Investigator(s)  
• Copy of the Investigator(s)’ current medical license(s), or equivalent  
• Signed and dated Non- Disclosure  Agreement(s) , if required  
• Signed and dated Certification/Financial Disclosure Form(s)  
16.[ADDRESS_608272] s in compliance with FDA and ICH/GCP guidelines. Documents 
must be retained until at least [ADDRESS_608273] receive written 
notification of this custodial change.  
   
 
 
 
Protocol: MC10- PTL-103, Revision [ADDRESS_608274] s. Investigators and 
associated IRB will be notified in writing in the event of termination.   
Possible reasons for study termination include:  
• The discovery of an unexpected, significant, or unacceptable risk to the subject s enrolled in 
the study.  
• A decision on the part of the Sponsor  to suspend or discontinue development of the device.  
16.9 Criteria for Suspending/Terminating an Investigational Site  
The Sponsor  reserves the right to stop the enrollment of subject s at an investigational site at any time 
after the study initiation visit if no subject s have been enrolled or if the center has multiple or severe 
protocol violations without justification or fails to follow remedial actions.  
Possible reasons for suspending/terminating a study center include:  
• Failure to obtain written Informed Consent.  
• Failure to report SAE or UADE  to the Sponsor  within 24 hours of knowledge.  
• Failure to complete data forms prior to the scheduled monitoring visits.  
• Loss of (or unaccounted for) investigational product inventory.  
16.[ADDRESS_608275] this trial appropriately, ensuring proper monitoring 
of the investigation, and that IRB  review and approval are obtained, and ensuring that the 
Investigators and the reviewing IRB  are promptly notified of significant new information about this 
investigation.  
Specifically, the Sponsor will be responsible for:  
• Securing compliance with the clinical protocol, Investigator Agreement, and federal, state and 
local regulations;  
• Conducting evaluations of all adverse events;  
• Controlling the distribution of the device(s) under investigation;  
• Maintaining records and repor ts; 
• Analyzing and reporting data;  
• Designating appropriately qualified medical personnel to be available to advise on study -
related medical questions or problems  
• Addressing any device -related inquiries outside the expertise of the site staff.  
16.11  Investigator R esponsibilities  
• Agree to sign and adhere to the Investigator Agreement . 
• Obtain approval fr om the IRB  including subsequent protocol amendments and changes to the 
Informed Consent form and obtaining annual IRB approval and renewal throughout the 
duration of the study.  
   
 
 
 
Protocol: MC10- PTL-103, Revision 00  42 
Confidential  
• Await IRB approval, as well as, any additional hospi[INVESTIGATOR_474615].  
• Complete and provide signed copi[INVESTIGATOR_474616].  
• Be willing to perform and be capable of performing study procedures as outlined in this 
protocol . 
• Comply with all required elements of this protocol (e.g., perform testing and follow -up as 
specified, especiall y during personnel transitions).  
• Agree to obtain written Informed Consent before any study specific procedures are performed 
in accordance with GCP . 
• Control Secure storage area for any investigational device(s) stored at their site.  
• Be aware of, and comply  with, GCP and applicable regulatory requirements . 
• Permit monitoring and auditing by [CONTACT_1034] , and inspection by [CONTACT_45979] . 
• Have available an adequate number of qualified staff and adequate facilities to properly 
conduct the study . 
• Ensure that study personnel are adequately informed about the protocol, the investigational 
device and study -related duties and functions.  
• Provide subject support for device- related questions and subsequently contact [CONTACT_474651].  
 
 
  
   
 
 
 
Protocol: MC10- PTL-103, Revision 00  43 
Confidential  
 
 
17.0 REVISION HISTORY  
 
Date  Description  
 Version 0 0.  Initial Release . 
 
   
 
 
 
Protocol: MC10- PTL-103, Revision 00  44 
Confidential  
18.0 BIBLIOGRAPHY  
                                                 
 
1 S. Patel, et al., “ Monitoring Motor Fluctuations in Patients w ith Parkinson’s Disease Using Wearable 
Sensors ”, IEEE Trans. Info. Tech in Biomed. , vol. 13, no. 6, Nov 2009.  
2 Jamie Adams, MD et al., “ Wearable Sensors for the Objective Measurement of Motor Features of 
Huntington Disease –  a Pi[INVESTIGATOR_16116] ”, Huntington Study Group, Nashville, TN , Nov 2016 . 
3 Moon, Y. et al. “Monitoring of gait in Multiple Sclerosis with novel wearable motion sensors ”, PLOS 
ONE , 2017.  
4 Kelly, J.M., Strecker, R.E., Bianchi, M.T., “ Recent Developments in Home Sleep- Monitoring Devices ”, 
ISRN Neurology , vol. 2012, art. 768794, 2012.  
5 Schultz, K. et al. “The Days of the Holter Monitor Are Numbered: Extended Continuous Rhythm 
Monitoring Detects More Clinically Significant Arrhythmias in Adults with Congenital Heart Disease”, 
Amer ican Heart Association Scientific Sessions, vol. 134, Nov 2016.  
6 McGinnis, R.S. et al. “ Skin Mounted Accelerometer System for Measuring Knee ROM”,  8th Annual 
International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) , 2016.  
7U.S. FDA Guidance for Industry: Assessing Adhesion with Transdermal Delivery Systems and Topi[INVESTIGATOR_474617] (June, 2016).  
8ISO [ZIP_CODE]- 10:2010 “Biological evaluation of medical devices Part 10: Tests for irritation and skin 
sensitization”, Annex C, Page 45, 2010.  
9ISO [ZIP_CODE]- 10:2010 “Biological evaluation of medical devices Part 10: Tests for irritation and skin 
sensitization”, Annex C, Page 45, 2010.  
10Investigational Device Ex emptions, 21 C.F.R. § 812.3(m), 2016.  
 